Metoprolol Alvogen (Metoprolol Succinate)

Metoprolol Alvogen is a beta‑adrenergic blocker that acts on the cardiovascular system to control blood pressure and heart workload.

• Hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Chronic heart failure: improves ventricular function and reduces hospitalization.
• Post‑myocardial infarction prophylaxis: lowers the chance of recurrent cardiac events.
• Certain cardiac arrhythmias: stabilises heart rhythm by slowing conduction through the AV node.

• Metoprolol selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation. This reduces heart rate, myocardial contractility, and cardiac output, leading to decreased oxygen demand and lower arterial pressure while preserving β2‑mediated bronchial tone.

Metoprolol may cause a range of adverse reactions.

Common Side Effects

• Fatigue or tiredness
• Dizziness or light‑headedness
• Bradycardia (slow heart rate)
• Cold extremities
• Gastrointestinal discomfort
• Headache

Serious or Rare Side Effects

• Severe bradycardia or heart block
• Acute hypotension
• Bronchospasm in susceptible patients
• Allergic skin reactions
• Depression or mood changes
• Worsening heart failure symptoms

Before initiating therapy, clinicians should assess individual risk factors and monitor response.

• Monitor blood pressure: ensure target values are achieved without excessive drop.
• Assess heart rate: watch for bradycardia, especially in patients with conduction disorders.
• Use caution in asthma or chronic obstructive pulmonary disease: β1 selectivity may not fully prevent bronchospasm.
• Adjust dose in renal impairment: reduced clearance may increase exposure.
• Avoid abrupt discontinuation: taper to prevent rebound tachycardia or hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metoprolol can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Verapamil or diltiazem: additive AV‑node depression may cause severe bradycardia.
• Clonidine withdrawal: sudden stop can precipitate hypertensive crisis when combined.
• Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may enhance hypotensive effect.
• Diuretics: combined use can lead to excessive blood pressure reduction.
• SSRIs or other antidepressants: may increase risk of bradycardia.